A Study of L-735,524 in HIV-Positive Children and Adolescents

Inclusion Criteria Patients must have: * HIV positivity. * No active opportunistic infection within the past 30 days, other than superficial candidiasis of the oral cavity or vagina. * Body surface area at least 1.0 sqm. * Consent of parent or guardian. Prior Medication: Allowed: * Aerosolized pentamidine. * Topical antifungals. * TMP / SMX. * AZT. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Significant hepatic disease including HBsAg or hepatitis C positivity. * Significant neurologic disease such as loss of intellectual ability, motor deficits, or seizure disorder. * Significant cardiac disease including dysrhythmia or cardiomyopathy. * Significant medical condition or laboratory abnormality that may pose additional risk to patient on study or confound the results. * Has a social situation that may interfere with study participation. Concurrent Medication: Excluded: * Oral contraceptives. Patients with the following prior conditions are excluded: * History of serious allergic drug reactions. * History of significant cardiac disease. * Participation on another clinical trial within the past 4 weeks. * Donated blood within the past 4 weeks. Prior Medication: Excluded within the past 4 weeks: * Hematopoietic growth factors. Excluded within the past 2 weeks: * Antiretroviral agent other than zidovudine. * Oral contraceptives. * Prophylaxis for opportunistic infections, other than aerosolized pentamidine, topical antifungals, and TMP/SMX. * Any other medication unless approved by Merck clinical monitor. Current illicit drug use.